Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer

Jinani Jayasekera ¹, Joseph A Sparano ², Robert Gray ³, Claudine Isaacs ¹, Allison Kurian ⁴, Suzanne O'Neill ¹, Clyde B Schechter ⁵, Jeanne Mandelblatt ¹

Affiliations

¹ Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.
² Department of Oncology at Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
³ Department of Biostatistics at Harvard University and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
⁴ Departments of Medicine and of Health Research and Policy, Stanford University School of Medicine, Stanford University, Palo Alto, CA.
⁵ Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.

PMID: 32337487
30 References

Abstract

Purpose: The Trial Assigning Individualized Options for Treatment (TAILORx) found chemotherapy could be omitted in many women with hormone receptor-positive, HER2-negative, node-negative breast cancer and 21-gene recurrence scores (RS) 11-25, but left unanswered questions. We used simulation modeling to fill these gaps.

Methods: We simulated women eligible for TAILORx using joint distributions of patient and tumor characteristics and RS from TAILORx data; treatment effects by RS from other trials; and competing mortality from the Surveillance, Epidemiology, and End Results program database. The model simulations replicated TAILORx design, and then tested treatment effects on 9-year distant recurrence-free survival (DRFS) in 14 new scenarios: eight subgroups defined by age (≤50 and >50 years) and 21-gene RS (11-25/16-25/16-20/21-25); six different RS cut points among women ages 18-75 years (16-25, 16-20, 21-25, 26-30, 26-100); and 20-year follow-up. Mean hazard ratios SD, and DRFS rates are reported from 1000 simulations.

Results: The simulation results closely replicated TAILORx findings, with 75% of simulated trials showing noninferiority for chemotherapy omission. There was a mean DRFS hazard ratio of 1.79 (0.94) for endocrine vs chemoendocrine therapy among women ages 50 years and younger with RS 16-25; the DFRS rates were 91.6% (0.04) for endocrine and 94.8% (0.01) for chemoendocrine therapy. When treatment was randomly assigned among women ages 18-75 years with RS 26-30, the mean DRFS hazard ratio for endocrine vs chemoendocrine therapy was 1.60 (0.83). The conclusions were unchanged at 20-year follow-up.

Conclusions: Our results confirmed a small benefit in chemotherapy among women aged 50 years and younger with RS 16-25. Simulation modeling is useful to extend clinical trials, indicate how uncertainty might affect results, and power decision tools to support broader practice discussions.

Other Links

Free PMC article
Full text on JNCI cancer spectrum

References

References
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark. less N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335 Highly Cited.
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Mitch Dowsett, Jack Cuzick, +16 authors, Richard Peto. less J Clin Oncol, 2009 Dec 02; 28(3). PMID: 19949017 Highly Cited.
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. Jinani Jayasekera, Yisheng Li, +21 authors, CISNET-BOLD Collaborative Group. less J Natl Cancer Inst, 2018 May 03; 110(12). PMID: 29718314 Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark. less J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680 Highly Cited.
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Jeanne S Mandelblatt, Natasha K Stout, +25 authors, Kathleen A Cronin. less Ann Intern Med, 2016 Jan 13; 164(4). PMID: 26756606 Free PMC article. Highly Cited.
NCCN Guidelines Insights Breast Cancer, Version 1.2016. William J Gradishar, Benjamin O Anderson, +28 authors, Rashmi Kumar. less J Natl Compr Canc Netw, 2015 Dec 15; 13(12). PMID: 26656517
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge. less N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962 Free PMC article. Highly Cited.
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. B Fisher, J Costantino, +7 authors, E R Fisher. less N Engl J Med, 1989 Feb 23; 320(8). PMID: 2644532 Highly Cited.
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. B Fisher, J Dignam, +10 authors, R G Margolese. less J Natl Cancer Inst, 1997 Dec 09; 89(22). PMID: 9390536
Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Hyunsoon Cho, Angela B Mariotto, +2 authors, Bhupinder S Mann, Carrie N Klabunde, Eric J Feuer. less Am J Epidemiol, 2013 Jul 05; 178(3). PMID: 23825168 Free PMC article.
Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model. Clyde B Schechter, Aimee M Near, +2 authors, Jinani Jayasekera, Young Chandler, Jeanne S Mandelblatt. less Med Decis Making, 2018 Mar 20; 38(1_suppl). PMID: 29554462 Free PMC article.
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. Clifford A Hudis, William E Barlow, +8 authors, Jo Anne Zujewski. less J Clin Oncol, 2007 May 22; 25(15). PMID: 17513820 Highly Cited.
Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Andrew Briggs. Value Health, 2005 Apr 22; 8(1). PMID: 15841888
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak. less NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379 Free PMC article. Highly Cited.
Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? G C Wishart, D C Greenberg, +4 authors, S W Duffy. less Br J Cancer, 2008 May 29; 98(11). PMID: 18506175 Free PMC article.
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. Charles E Geyer, Gong Tang, +8 authors, Norman Wolmark. less NPJ Breast Cancer, 2018 Nov 21; 4. PMID: 30456299 Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard. less Lancet, 2011 Dec 14; 379(9814). PMID: 22152853 Free PMC article. Highly Cited.
Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. Mitch Dowsett, Nicholas Turner. J Clin Oncol, 2019 Feb 12; 37(9). PMID: 30742561
Cancer statistics, 2018. Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin, 2018 Jan 10; 68(1). PMID: 29313949 Highly Cited.
Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. Yu Shen, Ying Yang, +3 authors, Donald A Berry. less J Natl Cancer Inst, 2005 Aug 18; 97(16). PMID: 16106024
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge. less N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917 Free PMC article. Highly Cited.
Online tool to guide decisions for BRCA1/2 mutation carriers. Allison W Kurian, Diego F Munoz, +5 authors, Sylvia K Plevritis. less J Clin Oncol, 2012 Jan 11; 30(5). PMID: 22231042 Free PMC article.
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. Sandra M Swain, Jong-Hyeon Jeong, +14 authors, Norman Wolmark. less N Engl J Med, 2010 Jun 04; 362(22). PMID: 20519679 Free PMC article.
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Harry J de Koning, Rafael Meza, +16 authors, Pamela M McMahon. less Ann Intern Med, 2014 Jan 01; 160(5). PMID: 24379002 Free PMC article. Highly Cited.
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. Hongchao Pan, Richard Gray, +9 authors, EBCTCG. less N Engl J Med, 2017 Nov 09; 377(19). PMID: 29117498 Free PMC article. Highly Cited.
The screening mammography paradox: better when found, perhaps better not to find. D A Berry. Br J Cancer, 2008 May 29; 98(11). PMID: 18506172 Free PMC article.
Risk for distant recurrence of breast cancer detected by mammography screening or other methods. Heikki Joensuu, Tiina Lehtimäki, +7 authors, Johan Lundin. less JAMA, 2004 Sep 02; 292(9). PMID: 15339900
Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools. Julia Foldi, Tess O'Meara, +3 authors, Lajos Pusztai. less J Clin Oncol, 2019 Apr 04; 37(16). PMID: 30943126
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. Gong Tang, Jack Cuzick, +6 authors, Norman Wolmark. less J Clin Oncol, 2011 Oct 20; 29(33). PMID: 22010013 Free PMC article.
Development of the 21-gene assay and its application in clinical practice and clinical trials. Joseph A Sparano, Soonmyung Paik. J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979 Highly Cited. Review.

BioKDE: Biomedical Knowledge Discovery Engine

Abstract

Other Links